Abstract: A cell culture comprising human foreskin cells, the human foreskin cells being capable of maintaining stem cells in an undifferentiated state when co-cultured therewith.

Abstract: This invention provides disc stem cells, processes for obtaining and culturing disc stem cells, and methods for repairing damaged or diseased disc tissue comprising the use of the disc stem cells of the invention.

Abstract: The present invention relates to hematopoietic cells, and more specifically to methods for long-term in vitro culturing and ex vivo expansion of hematopoietic cells. The present invention also provides compositions useful for culturing cells, such as media for culturing hematopoietic cells, specifically haematopoietic stem cells (HSC) and haematopoietic progenitor cells (HPC). The present invention further provides compositions including growth factor combinations and methods utilising altered growth and environmental conditions that are applicable in vitro culturing and to ex vivo expansion of HSC and/or HPC.

Abstract: Disclosed are methods for manipulating and expanding stem cell populations, including adult stem cells, the cells produced by such methods, and various protein constructs related thereto.

Abstract: A culture medium for human mesenchymal stem cells (hMSC) includes a mesenchymal stem cell basal medium; human leucocyte/platelet coat lysate; insulin; sodium selenite; ethanolamine; and basic fibroblast growth factor. This culture medium is effective for growing hMSC lines, including those which do not grow in culture medium normally used for this type of cell.

Abstract: The invention relates to the cell disruption of microbes and the preparation of the microbe proteins for mass spectrometric analysis. The cells of microbes from microcolonies are disrupted by physical or chemical means directly on the nutrient medium. The released proteins are then transferred to sample supports by direct contact with their contact surfaces; electrophoresis can be used for assistance. Once the proteins are firmly adsorbed on the contact surfaces, they can be washed with water in order to remove substances which interfere with the ionization process. For analysis by matrix-assisted laser desorption (MALDI), the proteins are prepared on the contact surfaces of the sample supports with matrix substances to form MALDI samples; the sample supports are then introduced into a MALDI mass spectrometer for the acquisition of mass spectra. The microbes are identified by similarity comparisons between the mass spectra of the microbe proteins and similarly obtained reference spectra.

Abstract: A method for forming at least a tooth root in a tooth containing a tooth crown, including: forming a culture core containing the tooth and a cell-containing base material, the tooth being wrapped with the cell-containing base material, and culturing the culture core in a medium to form at least the tooth root in the tooth contained therein, wherein the cell-containing base material contains at least one kind of cells selected from periodontal ligament-derived cells, bone marrow-derived cells, dental follicle-derived cells, dental pulp-derived cells and dental papilla-derived cells, and the medium contains a component contained in a conditioned medium of a serum-free-cultured cell line of a human uterocervical squamous carcinoma cell line; an additive containing at least one selected from IL-1?, IL-6, IL-8, IL-9, EGF, IGF-I, GH, PDGF-AB, VEGF, LIF, HGF, FGF-2, FGF-1, BMP-2, BMP-4, M-CSF, dexamethasone, insulin, thyroxine, thyrocalcitonin, ascorbic acid and ?-glycerophosphate; or both of them.

Abstract: We disclose a method of preparing a conditioned cell culture medium, the method comprising the steps of: (a) culturing a mesenchymal stem cell (MSC), a descendent thereof or a cell line derived therefrom in a cell culture medium; and (b) optionally isolating the cell culture medium; in which the mesenchymal stem cell (MSC) is obtained by propagating a cell obtained by dispersing a embryonic stem (ES) cell colony, or a descendent thereof, in the absence of co-culture in a serum free medium comprising FGF2.

Abstract: The invention provides a method of co-culturing mammalian muscle cells and mammalian motoneurons. The method comprises preparing one or more carriers coated with a covalently bonded monolayer of trimethoxysilylpropyl diethylenetriamine (DETA); suspending isolated fetal mammalian skeletal muscle cells in serum-free medium according to medium composition 1; suspending isolated fetal mammalian spinal motoneurons in serum-free medium according to medium composition 1; plating the suspended muscle cells onto the one or more carriers at a predetermined density and allowing the muscle cells to attach; plating the suspended motoneurons at a predetermined density onto the one or more carriers and allowing the motoneurons to attach; covering the one or more carriers with a mixture of medium composition 1 and medium composition 2; and incubating the carriers covered in the media mixture.

Abstract: The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.

Abstract: The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or ACCS), cell lysates derived therefrom, cell products derived therefrom, each alone or in combination.

Abstract: Provided is a composition for embryo culture, which contains a constitution suitable for embryo culture. Provided is a composition for embryo culture, which contains (a) a constitution shown in Table A below. TABLE A Components mM L-Alanine 0.297 ± 0.089 L-Asparagine 0.015 ± 0.005 L-Aspartic acid 0.120 ± 0.036 L-Glutamic acid 0.550 ± 0.165 Glycine 0.979 ± 0.294 L(?)-Proline 0.105 ± 0.032 L-Serine 0.176 ± 0.053 L(+)-Arginine 0.108 ± 0.032 L(?)-Cystine 0.048 ± 0.014 L-Histidine 0.053 ± 0.016 L(+)-Isoleucine 0.036 ± 0.011 L-Leucine 0.081 ± 0.024 L(+)-Lysine 0.176 ± 0.053 L-Methionine 0.022 ± 0.007 L(?)-Phenylalanine 0.045 ± 0.013 L(?)-Threonine 0.109 ± 0.033 L-Tryptophan 0.018 ± 0.005 L-Tyrosine 0.048 ± 0.014 L-Valine 0.108 ± 0.032 L-Glutamine or 0.398 ± 0.119 glutamine derivative Taurine 1.412 ± 0.

Abstract: The present invention relates to a tubule forming platform and an in vitro cardiovascular model for use in pharmacological studies. Furthermore, the invention relates to methods for the preparation said platform and model, and to a method of determining a biological activity of a test substance in said platform and cardiovascular model. Still further, the invention relates to an implantable cardiac structure for use in the treatment of cardiac disorders.

Abstract: Thermostable FGF-2 proteins having enhanced ability to support human pluripotent stem cell cultures are provided. Also provided are methods and compositions utilizing thermostable FGF-2 proteins.

Abstract: The present invention provide: a novel process for culturing animal cells and a kit for culturing animal cells, in which, even if the number of cells as sampled for biopsy is extremely small, the proliferation can sufficiently be maintained so as to enable to carry out various culture and/or tests, especially anticancer agent sensitivity tests, and the contamination with bacteria can be inhibited without damaging physiological activity of cells, especially sensitivity to anticancer agents. The process for culturing animal cells, according to the present invention, comprises the step of culturing a sample containing animal cells obtained from living body tissue in order to subject the sample to further culture and/or a test, with the process being characterized in that a culture medium is used wherein the culture medium has a proliferating action and physiological activity-retaining action on the animal cells, and further has a killing action and/or multiplication-inhibition action on bacteria.

Abstract: This invention relates to a method for producing cardiomyocytes and/or cardiac progenitor cells, comprising culturing an induced pluripotent stem (iPS) cell or embryonic stem (ES) cell, which has been differentiated into a mesoderm cell, in the presence of cyclosporin-A.

Abstract: Described herein are cell culture media, kits and methods for preparing cell culture media, and methods for culturing cells, for example, cells of the female reproductive tract, and tumor cells.

Abstract: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.

Abstract: Disclosed herein are reagent-cell complexes comprising one or more definitive endoderm cells. Also described herein are compositions for detecting definitive endoderm. Method of enriching, isolating and/or purifying definitive endoderm cells are also disclosed.

Abstract: A medium is described for the protein-free and serum-free cultivation of cells, especially mammalian cells, whereby the medium contains a proportion of soy hydrolysate.

Abstract: A avian cell line that supports replication of animal or human viruses, which cell line is adapted to animal-product free growth. The cell line is useful for propagating a virus suitable as a live or a killed vaccine and for virus isolation and diagnostic assays.

Abstract: This application relates to an in vitro method of producing a polyclonal IgG preparation. The method comprises (i) placing a polyclonal B-cell population enriched in IgG-secreting B cells in a culture medium; and (ii) culturing the polyclonal B-cell population under conditions enabling the production of the polyclonal IgG preparation from the polyclonal B-cell population. This improved method enables the production of antibodies (preferably IgG) and facilitates long-term culture of polyclonal B-cell populations.

Abstract: The present invention encompasses compositions for deriving, maintaining, and growing pluripotent and germ-line competent mammalian embryonic stem cells, and for deriving, maintaining, and growing adult human stem cells and/or adult early progenitor cells. Such compositions comprising a conditioned medium of a cell line expressing limited amounts of Leukemia Inhibitory Factor (LIF). The media of the present invention are used or for the generation of pluripotent and germ-line competent embryonic stem cells of mammals, and for the generation of adult human stem cells and/or adult early progenitor cells.

Abstract: The present invention relates to compositions and methods for maintaining undifferentiated pluripotent stem cell cultures.

Abstract: Provided herein are compositions and methods for forming fibrochondrocytes or fibrochondrocyte-like cells from progenitor cells, such as mesenchymal stem cells. One aspect provides a fibrochondrocyte culture medium including CTGF and TGF?3, optionally encapsulated by microspheres having different release profiles. Another aspect provides a method for forming fibrochondrocytes or fibrochondrocyte-like cells from progenitor cells by culturing with CTGF and TGF?3.

Abstract: The present invention provides a cytokine-based culture method for ex vivo expansion of NK cells from postembryonic hematopoietic stem cells into a fully closed, large-scale, cell culture bioprocess. We optimized enrichment of CD34+ cells followed by efficient expansion in gas-permeable cell culture bags. Thereafter, expanded CD34+ cells could be reproducibly amplified and differentiated into CD56+CD3? NK cell products with a mean expansion of more than 2,000 fold and a purity of >90%. Also provided are collections of cultured cells having specific properties.

Abstract: The present invention relates to a method of modulating apoptosis of a granulosa cell. The method includes one or more of the following steps: (i) modulating the concentration and/or activity of BMP-15 and/or BMP-6 that the granulosa cell is exposed to; (ii) modulating activity of a BMP-15 dependent signalling pathway in the granulosa cell; and (iii) modulating activity of a BMP-6 dependent signalling pathway in a granulosa cell.

Abstract: The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.

Abstract: The present invention relates to cell culture methods and compositions that are essentially serum-free and comprise a basal salt nutrient solution and an ErbB3 ligand.

Abstract: The present invention provides a method for inducing differentiation of pluripotent stem cells into mesodermal cells, comprising the step of culturing pluripotent stem cells in a serum-free medium without forming an embryoid body and without coculturing with cells from a different species.

Abstract: The present invention is of methods of establishing and propagating human embryonic stem cell lines using feeder cells-free, xeno-free culture systems and stem cells which are capable of being maintained in an undifferentiated, pluripotent and proliferative state in culture which is free of xeno contaminants and feeder cells.

Abstract: The present invention relates to a culture medium suitable for inducing dendritic cell differentiation comprising an effective amount of secretory immunoglobulins A (SIgA) and also to a method for obtaining a population of tolerogenic dendritic cells from cells, in particular monocytes. The present invention relates to uses of tolerogenic dendritic cells thus obtained in therapy and in induction of transplant tolerance.

Abstract: The invention relates to a method for culturing epithelial stem cells, isolated tissue fragments comprising the epithelial stem cells, or adenoma cells, and culturing the cells or fragments in the presence of a Bone Morphogenetic Protein (BMP) inhibitor, a mitogenic growth factor, and a Wnt agonist when culturing epithelial stem cells and isolated tissue fragments. The invention further relates to a cell culture medium comprising a BMP inhibitor, a mitogenic growth factor, and a Wnt agonist, to the use of the culture medium, and to crypt-villus organoids, gastric organoids and pancreatic organoids that are formed in the culture medium.

Abstract: The present invention relates to an improved cell culture additive with a content of polyamines and iron, media containing it and processes for using it for an improved cell growth, cell viability or cellular productivity.

Abstract: Methods and kits for propagating hematopoietic stem cells are provided. The methods comprise culturing cells in medium comprising one or more angiopoietin-like proteins, under conditions sufficient for expansion of HSCs. Angiopoietin-like proteins include angiopoietin-like protein 2, angiopoietin-like protein 3, angiopoietin-like protein 4, angiopoietin-like protein 5, angiopoietin-like protein 7, and microfibrillar-associated glycoprotein (Mfap4). Methods for identifying hematopoietic stem cells are provided and isolated hematopoietic stem cells are also provided.

Abstract: A method of enhancing the formation of extracellular matrix in culture. Cells in culture secrete most of the collagen into the media as unprocessed procollagen, i.e., the cells do not convert procollagen to collagen. In contrast, normal extracellular matrix deposition involves procollagen processing to collagen, fibril assembly and deposition into the cell layer to form a collagenous extracellular matrix. The addition of certain growth factors and the addition of a thin layer of a certain volume exclusion agent on top of the cells dramatically enhances the conversion of procollagen to collagen and will increase the amount of collagen and extracellular matrix associated with the cells. This invention advances bioengineering of connective tissues for medical applications that require an extensive and functional extracellular matrix with high tensile strength such as those in the cornea stroma, skin, tendons, ligaments, articular cartilage and the intervertebral disks.

Abstract: The present invention is generally in the field of neurological diseases and disorders, particular in the field of neurodegenerative diseases in which the myelin cover of nerves is lost. IL6R/IL6 chimera is used to promote the formation of oligodendrocytes from embryonic stem cells for treatment of neurodegenerative diseases or posttraumatic nerve damage.

Abstract: The disclosure provides methods and compositions useful for culturing stem cell including embryonic stem cells, adult stem cells, and embryonic germ cells.

Abstract: Compositions, and uses thereof, which are beneficial for eukaryotic cells in culture, and methods for their use in promoting cell growth, viability and recombinant protein expression. The methods disclosed in the present application are useful, for example, for improving cell viability and in accelerating the rate of cell growth of cells grown in culture. In one aspect, the supplements of the invention are useful for improving or enhancing the yield of the recombinant proteins from the cell cultures.

Abstract: A method for preparing serum and a serum preparation apparatus is provided that can give a large amount of serum with high culture efficiency regardless of freshness of blood used. In a method for preparing serum from blood containing at least platelets, a platelet processing step is provided in which platelet membrane in the blood is destroyed. After the platelet processing step, a deposition step for depositing thermolabile protein in blood and a removal step for removing the thermolabile protein, which has been deposited in the deposition step, are preferably provided.

Abstract: The present application discloses methods expanding SCs in an undifferentiated state, the methods comprising incubating undifferentiated SCs in suspension within a culture system comprising basic medium and knockout serum replacement (KOSR). The methods may also be applicable for selective spontaneous or directed differentiation of SCs into a selected population of somatic cells from a culture system of SCs in suspension, the method further comprising incubating said undifferentiated SCs in culture system that support respectively, spontaneous or directed differentiation of SCs into the selected population of somatic cells. The present application also discloses a culture system for expansion of stem cells (SCs) comprising a suspension of undifferentiated stem cells within basic medium and knockout serum replacement (KOSR). The methods and culture system of the invention may be used for large scale production of differentiated cells.

Abstract: Methods for increasing the stability of, or protecting, labile components such as ethanolamine, growth factors, vitamins, etc., in compositions such as a cell culture medium. Stability of the labile compound is increased either, by derivatization of the labile compound with chemicals, or by sequestering the labile compound. Sequestering can be done either by encapsulation within a microcapsule, or by the use of sequestering agents. Encapsulation includes the encapsulation of dendrimers complexes of susceptible compounds within the microcapsule, thereby providing the controlled release of the susceptible compound that was protected. These methods may improve and extend storage conditions of compositions comprising the labile compounds, improve shipping and handling of compositions comprising the labile compounds, such as dry media formulations, at room temperature rather than at lower temperatures thereby decreasing shipping costs.

Abstract: The present invention discloses a cell culturing formulation and a culturing and quantification method of CD140b+ cells thereof. The cell culturing formulation is applicable for inducing the growth of the CD140b+ cells in peripheral blood. The cell culturing formulation comprises a culturing medium, a serum, a mixed additive and a defined factor. Wherein, concentrations of the culturing medium, the serum, the mixed additive and the defined factor are 59˜98% (v/v), 0.1˜20% (v/v), 1˜10% (v/v) and 10?7˜10% (v/v) respectively.

Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.

Abstract: The present invention provides defined serum-free cell culture media useful in culturing fibroblasts, especially articular chondrocytes, that avoid problems inherent in the use of serum-containing media. The defined media comprise platelet-derived growth factor (PDGF), chemically defined lipids, oncostatin M (OSM), interleukin-6 (IL-6), leukemia inhibitory factor (LIF), or combinations of these compounds. In another aspect, the present invention also provides tissue culture methods that comprise incubating chondrocytes in the defined serum-free media. The methods enhance attachment and proliferative expansion of chondrocytes seeded at low density while maintaining their redifferentiation potential.

Abstract: A method for enhancing bone marrow cells, peripheral blood, and umbilical cord blood engraftment is disclosed wherein at least one of a granulocyte colony stimulating factor and a granulocyte macrophage colony stimulating factor, and optionally romiplostim, and optionally an erythropoiesis-stimulating agent, are added thereto for enhancing the engraftment of CD44 cells within the bone marrow cells, peripheral blood, and umbilical cord blood. Also provided is a method for enhancing a stem cell infusion by activating an up-regulation of a AF1q/CD44 signaling pathway. A stem cell product is disclosed having treated stem cells conditioned for activating an up-regulation of a AF1q/CD44 signaling pathway.

Abstract: The present invention relates to a glioma stem cell population, wherein the glioma stem cells do not present a telomerase activity and to a method for obtaining such cells.

Abstract: The present invention relates to methods for expanding a stem cell population. More particularly, the invention relates, inter alia, to methods and compositions for expanding a stem cell population, particularly a hematopoietic stem cell population.

Abstract: Provided herein are coatings for stem cell cultureware comprising poly-L-ornithine and bovine fibronectin and methods for preparing coated stem cultureware comprising contacting cultureware with poly-L-ornithine and contacting the cultureware with bovine fibronectin. Also provided are stem cell culture media comprising epidermal growth factor, beta-fibroblast growth factor and N2 supplement.

Abstract: A method of preparing differentiated NK cells by ex vivo expansion includes the steps of; (1) isolating a plurality of CD34+ hematopoietic cells; (2) culturing the cells in a medium, wherein the medium includes an effective amount of a notch ligand and one or more cytokines selected from the group consisting of IL-7, IL-15, SCF, Flt-3, IL-3 and IL-6; and (3) maintaining the cells in culture for a duration of time sufficient to produce NK cells.